SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

Rhea-AI Summary

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, has announced an upcoming CEO interview. Eric Schlorff, the company's CEO, will appear on the Benzinga All Access Show today, April 30, 2025, at approximately 10:50 am Eastern Time.

The live interview will be broadcast on YouTube, and viewers can access it through the provided link. For those unable to watch the live broadcast, a recording will be made available afterward on SeaStar Medical's website in the investor relations section, specifically on the Events and Presentations page.

Positive

• CEO media appearance on Benzinga All Access show increases company visibility to potential investors

Negative

• None.

DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30^th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show.

The event will be broadcast live and can be viewed at https://youtube.com/live/ki1hFktn_2Y?feature=share. An archived recording of the presentation will be available on the investor relations section of the Sea Star Medical’s website on the Events and Presentations page.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:  
IR@SEASTARMED.COM

FAQ

When is SeaStar Medical (ICU) CEO appearing on Benzinga All Access show?

SeaStar Medical CEO Eric Schlorff is appearing on Benzinga All Access show on April 30, 2025, at approximately 10:50 am Eastern Time.

How can I watch SeaStar Medical's (ICU) Benzinga All Access interview live?

You can watch the live broadcast of SeaStar Medical's Benzinga All Access interview at https://youtube.com/live/ki1hFktn_2Y?feature=share.

Where can I find the replay of SeaStar Medical's (ICU) Benzinga interview?

The archived recording of the presentation will be available on the Events and Presentations page in the investor relations section of SeaStar Medical's website.

What does SeaStar Medical (ICU) specialize in as a healthcare company?

SeaStar Medical is a commercial-stage healthcare company that focuses on transforming treatments for critically ill patients facing organ failure and potential loss of life.

Is SeaStar Medical (ICU) a publicly traded company?

Yes, SeaStar Medical is publicly traded on the Nasdaq stock exchange under the ticker symbol ICU.